The Wall Street Journal: Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market

the-wall-street-journal:-bio-rad-and-german-based-biotech-qiagen-weighing-latest-tie-up-in-medical-diagnostic-market

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

The talks have been going on for a while, but any agreement isn’t likely for another few weeks or more — and there may not be one.

Qiagen QGEN, +3.18% QIA, -4.30% had a market value of nearly $10 billion as of Monday’s close. Bio-Rad’s BIO, -8.39% BIO.B, -11.80% market value was $11.6 billion after its class A common shares fell 8.4% to $392.95 following the Wall Street Journal’s report on the deal talks.

A deal between Qiagen and Bio-Rad would be the latest tie-up in the medical-diagnostic market, which has grown as the pandemic helped increase demand for testing. 

An expanded version of this report appears at WSJ.com.

Trending at WSJ.com:

The two words that terrify junior employees

Paris cuts the lights to save energy. Will it help?

More biotech and health news:

Boston health officials worried about levels of COVID in wastewater

Israeli biotech Polyrizon to offer 3.1 million units in IPO priced at $5.20 to $7.20 each

This biotech company is lowering the cost of gene sequencing

Related Articles

Responses

Your email address will not be published. Required fields are marked *